314 related articles for article (PubMed ID: 33388011)
21. The modern management of uterine fibroids-related abnormal uterine bleeding.
Vannuccini S; Petraglia F; Carmona F; Calaf J; Chapron C
Fertil Steril; 2024 May; ():. PubMed ID: 38723935
[TBL] [Abstract][Full Text] [Related]
22. Fibroid growth and medical options for treatment.
Chabbert-Buffet N; Esber N; Bouchard P
Fertil Steril; 2014 Sep; 102(3):630-9. PubMed ID: 25171950
[TBL] [Abstract][Full Text] [Related]
23. Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Ali M; A R S; Al Hendy A
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):427-437. PubMed ID: 33682578
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic management of uterine fibroid tumors.
Puchar A; Feyeux C; Luton D; Koskas M
Minerva Ginecol; 2016 Aug; 68(4):466-76. PubMed ID: 26698838
[TBL] [Abstract][Full Text] [Related]
25. Diagnosis and management of uterine fibroids: current trends and future strategies.
Ahmad A; Kumar M; Bhoi NR; Badruddeen ; Akhtar J; Khan MI; Ajmal M; Ahmad M
J Basic Clin Physiol Pharmacol; 2023 May; 34(3):291-310. PubMed ID: 36989026
[TBL] [Abstract][Full Text] [Related]
26. Role of Medical Management for Uterine Leiomyomas.
Kashani BN; Centini G; Morelli SS; Weiss G; Petraglia F
Best Pract Res Clin Obstet Gynaecol; 2016 Jul; 34():85-103. PubMed ID: 26796059
[TBL] [Abstract][Full Text] [Related]
27. Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids.
Lynch SE; Mayer DC
Ann Pharmacother; 2022 Jan; 56(1):93-101. PubMed ID: 33998300
[TBL] [Abstract][Full Text] [Related]
28. Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids.
Talaulikar VS; Manyonda IT
Adv Ther; 2012 Aug; 29(8):655-63. PubMed ID: 22903240
[TBL] [Abstract][Full Text] [Related]
29. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2001; (2):CD000547. PubMed ID: 11405968
[TBL] [Abstract][Full Text] [Related]
30. The potential role of elagolix for treating uterine bleeding associated to uterine myomas.
Barra F; Vitale SG; Seca M; Scala C; Leone Roberti Maggiore U; Cianci A; Ferrero S
Expert Opin Pharmacother; 2020 Aug; 21(12):1419-1430. PubMed ID: 32401547
[TBL] [Abstract][Full Text] [Related]
31. Selective Progesterone Receptor Modulators for the Medical Treatment of Uterine Fibroids with a Focus on Ulipristal Acetate.
Rabe T; Saenger N; Ebert AD; Roemer T; Tinneberg HR; De Wilde RL; Wallwiener M
Biomed Res Int; 2018; 2018():1374821. PubMed ID: 30539001
[TBL] [Abstract][Full Text] [Related]
32. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
Brazert M; Korman MP; Pawelczyk LA
Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
[TBL] [Abstract][Full Text] [Related]
33. The current place of medical therapy in uterine fibroid management.
Donnez J; Donnez O; Dolmans MM
Best Pract Res Clin Obstet Gynaecol; 2018 Jan; 46():57-65. PubMed ID: 29169896
[TBL] [Abstract][Full Text] [Related]
34. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
[TBL] [Abstract][Full Text] [Related]
35. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
Donnez J; Donnez O; Dolmans MM
Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
[TBL] [Abstract][Full Text] [Related]
36. Contemporary approaches in the management of uterine leiomyomas.
Singh S; Kumar P; Kavita ; Rathore SS; Singh Y; Garg N
Eur J Obstet Gynecol Reprod Biol; 2023 Aug; 287():195-210. PubMed ID: 37385088
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic management of uterine fibroid tumors: updated French guidelines.
Marret H; Fritel X; Ouldamer L; Bendifallah S; Brun JL; De Jesus I; Derrien J; Giraudet G; Kahn V; Koskas M; Legendre G; Lucot JP; Niro J; Panel P; Pelage JP; Fernandez H;
Eur J Obstet Gynecol Reprod Biol; 2012 Dec; 165(2):156-64. PubMed ID: 22939241
[TBL] [Abstract][Full Text] [Related]
38. Selective Progesterone Receptor Modulators for the Treatment of Uterine Leiomyomas.
Safrai M; Chill HH; Reuveni Salzman A; Shushan A
Obstet Gynecol; 2017 Aug; 130(2):315-318. PubMed ID: 28697115
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial.
Al-Hendy A; Zhou YF; Faustmann T; Groettrup-Wolfers E; Laapas K; Parke S; Seitz C
F S Sci; 2023 Nov; 4(4):317-326. PubMed ID: 37437885
[TBL] [Abstract][Full Text] [Related]
40. Successes and failures of uterine leiomyoma drug discovery.
Ali M; Chaudhry ZT; Al-Hendy A
Expert Opin Drug Discov; 2018 Feb; 13(2):169-177. PubMed ID: 29254389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
